Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment

PURPOSE: Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC). Lenvatinib, a multikinase inhibitor, and pembrolizumab, a PD-1 inhibitor, have shown efficacy and tolerability in patients with HCC, and adding this combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Llovet, Josep M., Vogel, Arndt, Madoff, David C., Finn, Richard S., Ogasawara, Sadahisa, Ren, Zhenggang, Mody, Kalgi, Li, Jerry J., Siegel, Abby B., Dubrovsky, Leonid, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940827/
https://www.ncbi.nlm.nih.gov/pubmed/35119481
http://dx.doi.org/10.1007/s00270-021-03031-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940827/
https://www.ncbi.nlm.nih.gov/pubmed/35119481
http://dx.doi.org/10.1007/s00270-021-03031-9

Ejemplares similares